Treprostinil

Drug Profile

Treprostinil

Alternative Names: 15AU; 15AU81; ARD-1500; ARD-1550; BW 15AU; BW 15AU81; BW A15AU; LRX 15; MD-0701; Orenitram; Remodulin; Sustained-release treprostinil - United Therapeutics; TransCon treprostinil; Treprost; Treprostenol; Treprostinil diolamine; Treprostinol; Tresprostinol diethanolamine; Tyvaso; U 62840; Uniprost; UT 15; UT-15C; UT-15C SR

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; Pfizer
  • Developer Ascendis Pharma; Ferrer; Lees Pharmaceutical Holdings; Mochida Pharmaceutical; United Therapeutics Corporation
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary arterial hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase II Systemic scleroderma
  • Discontinued Cancer; Heart failure; Peripheral ischaemia

Most Recent Events

  • 06 Jan 2017 United Therapeutics plans a phase II trial for Pulmonary arterial hypertension in USA (IV and PO) (NCT03016468)
  • 05 Jan 2017 United Therapeutics plans a phase II trial for Pulmonary arterial hypertension associated with chronic obstructive pulmonary disease in USA (Inhalation) (NCT03012646)
  • 19 Dec 2016 United therapeutics plans a phase III trial for Pulmonary arterial hypertension (Adjunctive therapy) in USA (NCT02999906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top